Additional file 1 of Development and validation of a model and nomogram for breast cancer diagnosis based on quantitative analysis of serum disease-specific haptoglobin N-glycosylation

Additional file 1: Figure S1. Aggregation plots of missing values of clinical variables. The first plot shows the proportion of missing values in each variable. The second plot shows patterns of missing values. The frequencies of the corresponding combinations are demonstrated to the right. The blue bars represent missing values, while the orange bars represent observed values. Figure S2. Strip plots of observed and imputed data of clinicopathological variables. The strip plots display the distribution of imputed values (orange points) over observed values (blue points) in a combined way. In total, 5 multiple imputed data sets were created. Column 1 represents the original data set, while column 2-6 represent the 5 imputed data sets. The second imputed data set (column 3) was used. Most of its imputations were in a plausible range, and properly accounted for the distribution of the missing data. Figure S3. Histogram plots displaying propensity score distributions for the malignant and benign groups before and after propensity score matching (caliper = 0.333). Figure S4. Heatmap of the correlations of DSHp-β N-glycopeptides and tumor markers. The numbers in grid show the Spearman correlation coefficients. Blank indicates a Bonferroni correction p-value of ≥ 0.05. Table S1. Identified N-glycopeptides of DSHp-β, their potential structures, and intensities between benign breast diseases and breast cancer

Image_1_Breast-conserving surgery without axillary surgery and radiation versus mastectomy plus axillary dissection in elderly breast cancer patients: A retrospective study.jpeg

BackgroundThe high relative mortality rate in elderly breast cancer patients is most likely the result of comorbidities rather than the tumor load. Foregoing axillary lymph node dissection or omitting radiotherapy after breast-conserving surgery (BCS) does not affect the prognosis of elderly breast cancer patients. We sought to assess the safety of breast-conserving surgery without axillary lymph node dissection as well as breast and axillary radiotherapy (BCSNR) in elderly patients with early-stage breast cancer.MethodsWe retrospectively included 541 consecutive breast cancer patients aged over 70 years with clinically negative axillary lymph nodes in one clinical center. Of these patients, 181 underwent mastectomy plus axillary lymph node dissection (MALND) with negative axillary cleaning and 360 underwent BCSNR.ResultsAfter a median follow-up of 5 years, there was no significant difference between the BCSNR and MALND groups in either distant recurrence-free survival (DRFS) (p=0.990) or breast cancer-specific survival (p=0.076). Ipsilateral axillary disease was found in 11 (3.1%) patients in the BCSNR group and 3 (1.7%) patients in the MALND group; this difference was not significant (p=0.334). We did not observe a significant difference in distant recurrence between the groups (p=0.574), with 25 (6.9%) patients in the BCSNR group experiencing distant recurrence compared to 15 (8.3%) patients in the MALND group. Our findings did show a significant difference in ipsilateral breast cancer recurrence (IBTR), with 31 (8.6%) patients in the BCSNR group experiencing IBTR compared to only 2 (1.1%) patients in the MALND group (p=0.003).ConclusionBCSNR is a safe treatment option for elderly breast cancer patients with clinically negative axillary lymph nodes.</p

Flow chart for the selection of the included studies.

<p>Flow chart for the selection of the included studies.</p

Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis

<div><p>Background</p><p>The diagnostic performance of indocyanine green (ICG) fluorescence-guided sentinel lymph node biopsy (SLNB) for the presence of metastases in breast cancer remains unclear.</p><p>Objective</p><p>We performed a meta-analysis to investigate the diagnostic performance of ICG-guided SLNB.</p><p>Methods</p><p>Eligible studies were identified from searches of the databases PubMed and EMBASE up to September 2015. Studies that reported the detection rate of ICG fluorescence-guided SLNB with full axillary lymph node dissection and histological or immunohistochemical examinations were included. A meta-analysis was performed to generate pooled detection rate, sensitivity, specificity, false negative rate, diagnostic odds ratio (DOR) and a summary receiver operator characteristic curve (SROC).</p><p>Results</p><p>Nineteen published studies were included to generate a pooled detection rate, comprising 2594 patients. The pooled detection rate was 0.98 (95% confidence interval [CI], 0.96–0.99). Six studies finally met the criteria for meta-analysis, which yielded a pooled sensitivity of 0.92 (95% CI, 0.85–0.96), specificity 1 (95% CI, 0.97–1), and DOR 311.47 (95% CI, 84.11–1153.39). The area under the SROC was 0.9758. No publication bias was found.</p><p>Conclusion</p><p>ICG fluorescence-guided SLNB is viable for detection of lymph node metastases in breast cancer. Large-scale randomized multi-center trials are necessary to confirm our results.</p></div

Nineteen studies of the pooled detection rate analysis.

<p>Nineteen studies of the pooled detection rate analysis.</p

The pooled DOR was 311.47 (95% CI, 84.11–1153.39).

<p>The pooled DOR was 311.47 (95% CI, 84.11–1153.39).</p

Nineteen studies for the pooled detection rate analysis.

<p>Nineteen studies for the pooled detection rate analysis.</p

The pooled detection rates was 0.98 (95% confidence interval [CI], 0.96–0.99).

<p>The pooled detection rates was 0.98 (95% confidence interval [CI], 0.96–0.99).</p

Summary of receiver operator characteristic curves.

<p>Summary of receiver operator characteristic curves.</p

A Prognostic Model of Triple-Negative Breast Cancer Based on miR-27b-3p and Node Status

<div><p>Objective</p><p>Triple-negative breast cancer (TNBC) is an aggressive but heterogeneous subtype of breast cancer. This study aimed to identify and validate a prognostic signature for TNBC patients to improve prognostic capability and to guide individualized treatment.</p><p>Methods</p><p>We retrospectively analyzed the prognostic performance of clinicopathological characteristics and miRNAs in a training set of 58 patients with invasive ductal TNBC diagnosed between 2002 and 2012. A prediction model was developed based on independent clinicopathological and miRNA covariates. The prognostic value of the model was further validated in a separate set of 41 TNBC patients diagnosed between 2007 and 2008.</p><p>Results</p><p>Only lymph node status was marginally significantly associated with poor prognosis of TNBC (<i>P</i> = 0.054), whereas other clinicopathological factors, including age, tumor size, histological grade, lymphovascular invasion, P53 status, Ki-67 index, and type of surgery, were not. The expression levels of miR-27b-3p, miR-107, and miR-103a-3p were significantly elevated in the metastatic group compared with the disease-free group (<i>P</i> value: 0.008, 0.005, and 0.050, respectively). The Cox proportional hazards regression analysis revealed that lymph node status and miR-27b-3p were independent predictors of poor prognosis (<i>P</i> value: 0.012 and 0.027, respectively). A logistic regression model was developed based on these two independent covariates, and the prognostic value of the model was subsequently confirmed in a separate validation set. The two different risk groups, which were stratified according to the model, showed significant differences in the rates of distant metastasis and breast cancer-related death not only in the training set (<i>P</i> value: 0.001 and 0.040, respectively) but also in the validation set (<i>P</i> value: 0.013 and 0.012, respectively).</p><p>Conclusion</p><p>This model based on miRNA and node status covariates may be used to stratify TNBC patients into different prognostic subgroups for potentially individualized therapy.</p></div